Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

Table 2 CEA levels of 6 patients who showed temporary decrease during the vaccination

Patient	Baseline level (weeks) ¹ ²	Lowest level (weeks) *²	Percent reduction *³	Duration of the decrease in CEA
Case 1	15.9 ng/ml (0 week)	6.5 ng/ml (7 weeks)	59.1 %	12 weeks
Case 3	34.0 ng/ml (5 weeks)	30.4 ng/ml (9 weeks)	10.6%	6.5 weeks
Case 5	184.0 ng/ml (0 week)	159.2 ng/ml (2 weeks)	13.5 %	8 weeks
Case 6	19.5 ng/ml (8 weeks)	19.4 ng/ml (10 weeks)	0.5 %	2 weeks
Case 7	230.0 ng/ml (0 week)	150.2 ng/ml (2 weeks)	34.7 %	3.5 weeks
Case 9	78.3 ng/ml (0 week)	71.7 ng/ml (8 weeks)	8.4 %	11 weeks

*1 CEA level just before the decrease, *2 Period after the first vaccination, *3 (Baseline level – Lowest level) / Baseline level × 100 (%)

ISSN: 1479-5876